Wells Therapeutics World Class Team
Jing Ouyang
Head - China Operations
25 years of experience in corporate finance, fundraising, and cross-border investment.
​
Senior finance and investment professional with 25 years of experience in corporate finance, fundraising, and cross-border investments. Proven track record in leading capital raises for companies and funds, with strong, long-standing investor relationships in China and internationally.
Deep expertise in China’s healthcare sector, combining local market insight, government and stakeholder connections, and execution experience. Currently Managing Partner for Fundraising and Investor Relations at China Summit Capital, with prior senior roles at Noah Holdings and UT Starcom.
Kun Tao, CFA
CFA - CFO
20+ years of experience in finance and China–US cross-border licensing transactions.
​
Seasoned finance professional with over 20 years of experience in China–US cross-border licensing. Proven track record in deal sourcing and execution, having led 10 completed China–US licensing deals as Managing Director at Yafo Capital.
Former senior research analyst at Roth Capital and William O’Neil, with deep buy-side, sell-side, and private/secondary market research experience. Also served as CFO/Financial Controller at Acorn Corp.
Karuppiah Kannan, PhD
PhD - CDO
20+ years of experience in drug discovery, translational, and clinical development.
​
Experienced pharmaceutical executive with over 20 years in drug discovery and clinical development. Served as global program leader at Takeda for 7 oncology assets, advancing programs from pre-IND to proof-of-concept and early launch in solid tumors and hematologic cancers.
Managed a ~$500M clinical development budget, led extensive alliance management, and actively participated in business development. Previously led discovery and translational science for multiple preclinical assets at Aveo, Millennium, and Takeda.
Rob Kleinfield, PhD
PhD - CSO
25+ years of experience in drug development from lead optimization to life-cycle management.
​
Veteran pharma and biotech executive with 25+ years spanning lead optimization, development, and life-cycle management.
Led development and launch of multiple NMEs and efficacy supplements, including Cipro, Avelox, Trasylol, Precose, Torisel, and MEPACT. Managed programs at Bayer, Wyeth, and Takeda, including over 10 INDs, 20 pivotal Phase 3 trials, and 10 NDA/SNDAs. Served as CDO at Arvinas and Vivid Biosciences, leading preclinical programs that advanced AR and ER PROTACs to IND stage.
Executive Team
A Seasoned Team with Global Experience and China Access